{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:40:07Z","timestamp":1792010407578,"version":"4.4.0"},"reference-count":22,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda Development Center of Americas, Inc., Lexington, MA, USA"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2024,2,15]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A phase 1b double-blind, placebo-controlled, multicentre study was conducted in patients with SLE receiving standard background therapy. Eligible patients were adults who met the 2012 SLICC or ACR criteria for diagnosis, had a baseline SLE Disease Activity Index 2000 (SLEDAI-2K) score of \u22656\u2009and were positive for anti-double-stranded DNA antibodies and\/or anti-extractable nuclear antigens antibodies. Patients received 45 mg, 90 mg or 135 mg of mezagitamab or placebo every 3 weeks over 12 weeks. Primary endpoints were safety and tolerability. Secondary endpoints included pharmacokinetics and pharmacodynamics. Exploratory assessments included disease activity scales, deep immune profiling and interferon pathway analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>22 patients received at least one dose of either mezagitamab or placebo. In patients exposed to mezagitamab (n=17), drug was well tolerated. Adverse event (AEs) were balanced across treatment groups, with no treatment emergent AEs exceeding grade 2. Responder analyses for Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and SLEDAI-2K did not reveal any observable differences across treatment groups. However, there was a trend for more profound skin responses among patients with higher CLASI scores (&gt;10) at baseline. Pharmacodynamic analysis showed median CD38 receptor occupancy up to 88.4% on CD38+ natural killer cells with concurrent depletion of these cells up to 90% in the 135\u2009mg group. Mean reductions in IgG and autoantibodies were less than 20% in all dose groups. Cytometry by time of flight and type 1 interferon gene analysis revealed unique fingerprints that are indicative of a broad immune landscape shift following CD38 targeting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mezagitamab had a favourable safety profile in patients with moderate to severe SLE and elicited a pharmacodynamic effect consistent with CD38+ cell depletion. These findings reveal novel insights into the drug\u2019s mechanism of action and support the continued investigation of mezagitamab in autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2023-001112","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T13:10:24Z","timestamp":1709817024000},"page":"e001112","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03724916","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-7101","authenticated-orcid":false,"given":"Scott R P","family":"McDonnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-9340","authenticated-orcid":false,"given":"Van Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah M","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Merkwirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8916-3680","authenticated-orcid":false,"given":"Elena Tomaselli","family":"Muensterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-1585","authenticated-orcid":false,"given":"Richard A","family":"Furie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2024070106301953000_11.1.e001112.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102870","article-title":"Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies","volume":"132","author":"Li","year":"2022","journal-title":"J Autoimmun"},{"key":"2024070106301953000_11.1.e001112.2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236021","article-title":"Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus","volume":"20","author":"Ma","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2024070106301953000_11.1.e001112.3","doi-asserted-by":"crossref","DOI":"10.3390\/antib5010002","article-title":"Autoantibodies in SLE: Specificities, isotypes and receptors","volume":"5","author":"Dema","year":"2016","journal-title":"Antibodies (Basel)"},{"key":"2024070106301953000_11.1.e001112.4","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201041354"},{"key":"2024070106301953000_11.1.e001112.5","doi-asserted-by":"publisher","DOI":"10.1186\/ar3433"},{"key":"2024070106301953000_11.1.e001112.6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052424","article-title":"Dysregulated Cd38 expression on peripheral blood immune cell Subsets in SLE","volume":"22","author":"Burns","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024070106301953000_11.1.e001112.7","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.952304","article-title":"B cells in systemic lupus erythematosus: targets of new therapies and surveillance tools","volume":"9","author":"Parodis","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024070106301953000_11.1.e001112.8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2023325"},{"key":"2024070106301953000_11.1.e001112.9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open"},{"key":"2024070106301953000_11.1.e001112.10","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.198.Supp.224.20","article-title":"TAK-079 is a high affinity Monoclonal antibody that effectively mediates Cd38+ cell depletion","volume":"198","author":"Smithson","year":"2017","journal-title":"J Immunol"},{"key":"2024070106301953000_11.1.e001112.11","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.256602"},{"key":"2024070106301953000_11.1.e001112.12","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-Cd38 Cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2024070106301953000_11.1.e001112.13","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128007","article-title":"Preliminary results from a phase 1B study of TAK-079, an investigational anti-Cd38 Monoclonal antibody (mAb) in patients with Relapsed\/ refractory multiple myeloma (RRMM)","volume":"134","author":"Krishnan","year":"2019","journal-title":"Blood"},{"key":"2024070106301953000_11.1.e001112.14","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.11622.1","article-title":"Cytof Workflow: differential discovery in high-throughput high-dimensional Cytometry Datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res"},{"key":"2024070106301953000_11.1.e001112.15","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.22625"},{"key":"2024070106301953000_11.1.e001112.16","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btq170"},{"key":"2024070106301953000_11.1.e001112.17","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2594"},{"key":"2024070106301953000_11.1.e001112.18","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.4049\/jimmunol.143.10.3183","article-title":"Comparative studies of human Fcriii-positive and negative natural killer cells","volume":"143","author":"Nagler","year":"1989","journal-title":"J Immunol"},{"key":"2024070106301953000_11.1.e001112.19","doi-asserted-by":"publisher","DOI":"10.1038\/nri3795"},{"key":"2024070106301953000_11.1.e001112.20","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals Cd38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024070106301953000_11.1.e001112.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-011-2078-4"},{"key":"2024070106301953000_11.1.e001112.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102356","article-title":"Evolving story of Autoantibodies in systemic lupus erythematosus","volume":"110","author":"Pisetsky","year":"2020","journal-title":"J Autoimmun"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2023-001112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:37:05Z","timestamp":1719826625000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2023-001112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/lupus-2023-001112"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2023-001112","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}